Physician profile
Chenchen Zhang
NPI 1386051381
$7,138.07
in general payments reported to CMS, 2019-2025
15 companies · $720 in 2025
The $720 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $19.90 · 2021: $3,603 · 2022: $1,282 · 2023: $211 · 2024: $1,050 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481 · Education: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.68 |
| Education | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,891.23 | 2021-2025 | Da Vinci Surgical System |
| Pinnacle Biologics, INC | $1,510.99 | 2021-2025 | Photofrin |
| US Endoscopy | $1,050.06 | 2021 | |
| Noah Medical Corporation | $450.02 | 2024-2025 | Galaxy |
| Pulmonx Corporation | $424.29 | 2022-2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Steris Corporation | $246.84 | 2021 | |
| Genentech USA, INC. | $130.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.40 | 2019 | |
| Erbe USA INC | $97.28 | 2022 | |
| Lumenis, INC | $59.34 | 2021 | |
| Olympus America INC. | $58.07 | 2024 | Spiration Valve System |
| Merck Sharp & Dohme LLC | $32.31 | 2025 | Keytruda |
| Pfizer INC. | $28.28 | 2023 | |
| Novo Nordisk INC | $19.90 | 2020 | |
| Janssen Biotech, INC. | $16.94 | 2025 | Rybrevant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chenchen Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.